Cytotoxicity of Zardaverine in Embryonal Rhabdomyosarcoma from a Costello Syndrome Patient

Costello syndrome (CS) patients suffer from a very high 10% incidence of embryonal rhabdomyosarcoma (ERMS). As tools to discover targeted therapeutic leads, we used a CS patient-derived ERMS cell line (CS242 ERMS) harboring a homozygous p.G12A mutation in HRAS, and a control cell line derived from t...

Descripción completa

Detalles Bibliográficos
Autores principales: Cartledge, Donna M., Robbins, Katherine M., Drake, Katherine M., Sternberg, Rachel, Stabley, Deborah L., Gripp, Karen W., Kolb, E. Anders, Sol-Church, Katia, Napper, Andrew D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376947/
https://www.ncbi.nlm.nih.gov/pubmed/28421158
http://dx.doi.org/10.3389/fonc.2017.00042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376947/
https://www.ncbi.nlm.nih.gov/pubmed/28421158
http://dx.doi.org/10.3389/fonc.2017.00042

Ejemplares similares